BFRI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
12.0M
+19.0%
10.1M
-41.0%
17.1M
+144.7%
7.0M
-22.6%
9.0M
Cost of Revenue
2.4M
+13.9%
2.1M
-29.7%
3.0M
+47.1%
2.0M
-22.6%
2.6M
Gross Profit
9.6M
+20.4%
8.0M
-43.5%
14.1M
+185.1%
4.9M
-22.6%
6.4M
Operating Expenses
10.1M
-17.7%
12.3M
+28.9%
9.5M
-15.1%
11.2M
-2.1%
11.5M
R&D
448.0K
-50.2%
900.0K
+14.4%
787.0K
-7.8%
854.0K
-1.8%
870.0K
SG&A
9.7M
-12.1%
11.0M
+25.7%
8.7M
-15.6%
10.4M
-2.2%
10.6M
Operating Income
-524000
+87.9%
-4320000
-194.8%
4.6M
+172.6%
-6278000
-23.6%
-5079000
EBITDA
-459000
+89.2%
-4265000
-192.3%
4.6M
+173.9%
-6257000
-23.8%
-5053000
Net Income
-604000
+87.3%
-4752000
-184.3%
5.6M
+184.8%
-6649000
-24.9%
-5324000
EPS (Basic)
$-0.05
+87.8%
$-0.41
-185.4%
$0.48
+177.4%
$-0.62
-8.8%
$-0.57
EPS (Diluted)
$-0.05
+87.8%
$-0.41
-185.4%
$0.48
+177.4%
$-0.62
-8.8%
$-0.57
Shares (Diluted)
12.9M
+10.6%
11.7M
-0.0%
11.7M
+8.4%
10.8M
+15.2%
9.4M
Biofrontera (BFRI) โ€” Financials